News and Events - Cardionovum®

Latest press release

Nov 16, 2022

Late-Breaking Xlimit RCT data presented at CSC Congress demonstrate an equivalent performance of the Xlimus® DES in terms of OCT derived endpoints than the Synergy™ DES.

Bonn, Germany. November 16, 2022 – Data presented at Innovation session today at the CSC 2022 congress demonstrated an equivalent performance of the Xlimus® DES in terms of OCT derived endpoints than the Synergy™ DES, including Neointimal Volume and Neointimal Volume weighted by length at 6 months. Secondary endpoints, including other OCT parameters, such as in-stent Minimum Lumen Area (MLA) and percentage of strut coverage as well as clinical endpoints, showed no significant differences between the two groups in any of the evaluated parameters within the Xlimit RCT.

Learn more >> Late-Breaking Xlimit RCT data presented at CSC Congress demonstrate an equivalent performance of the Xlimus® DES in terms of OCT derived endpoints than the Synergy™ DES.

Nov 07, 2022

Prof. Matteo Tozzi discusses about new data bolster safety and effectiveness of Safepax®

Prof. Matteo Tozzi (Varese, Italy) speaks to Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting in Barcelona (Spain) about his new study that analyzes the concentrations of paclitaxel in the bloodstream after the use of a Drug-Coated Balloons (DCBs) in AVFs.

Learn more >> Prof. Matteo Tozzi discusses about new data bolster safety and effectiveness of Safepax®

Sep 09, 2022

CARDIONOVUM® announces regulatory approval of APERTO® OTW in Mexico

We are proud to announce that we have received the authorization by the Secretaria de Salud and COFEPRIS to distribute APERTO® OTW in Mexico.

Learn more >> CARDIONOVUM® announces regulatory approval of APERTO® OTW in Mexico

Aug 02, 2022

Cardionovum® announces First Procedure in Hyper II International Clinical Trial.

CARDIONOVUM® today announced the enrollment of the first patient in the International Hyper II Clinical Study

Learn more >> Cardionovum® announces First Procedure in Hyper II International Clinical Trial.

June 08, 2022

CARDIONOVUM® announces the first Signature RCT patient enrollment

On June 8th, in Sankt Gertrauden hospital in Berlin, Germany, the first Signature RCT patient has been enrolled

Learn more >> CARDIONOVUM® announces the first Signature RCT patient enrollment

Mar 31, 2021

CARDIONOVUM announces completion of patients enrolment in XLIMIT Trial

Trial designed to evaluate non inferiority of XLIMUS DES vs SYNERGY EES in terms of reendothelialization assessed with OCT in patients undergoing percutaneous coronary intervention

Learn more >> CARDIONOVUM announces completion of patients enrolment in XLIMIT Trial

Upcoming events

Currently there are no events.

Latest events

Cardionovum at EuroPCR 18, 19, 20 May 2021 Cardionovum at EuroPCR 18, 19, 20 May 2021

Cardionovum invites you to participate in on demand interviwes:

XLIMIT Trial RCT, with Dr. Luca Testa from Italy.
Goal: to assess angiographic and clinical performance of the Xlimus Biodegradable Polymer Sirolumus-eluting stent versus a gold standard like Synergy Biodegradable Polymer Everolimus Stent in patients treated with percutaneous coronary angioplasty.
Hyper Registry with Dr. Alfonso Ileasi from Italy.
Goal: Asses the clinical results after a Hybrid Approach in diffuse CAD lesions longer tan 28mm combinig Restore DCB and New generation DES.

Date: May 18, 2021–May 21, 2021

Cardionovum at EuroPCR 18, 19, 20 May 2021 Learn more >>